Edition:
India

Personal Genome Diagnostics enteres into a collaboration with Five Prime Therapeutics


Tuesday, 3 Apr 2018 

April 3 (Reuters) - Five Prime Therapeutics Inc ::ONCOLOGY DRUG CANDIDATE BEMARITUZUMAB.CO INTENDS TO SUBMIT ASSAY FOR REGULATORY APPROVAL, COMMERCIALIZE IN U.S., EUROPE, JAPAN, CHINA, OTHER COUNTRIES.FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED. 

Company Quote

5.59
0.0 +0.00%
19 Jul 2019